Tunable Luminescent Organic Salts for Enhanced Imaging and Photodynamic Therapy
Summary
EPO granted patent EP3664892A2 to Board of Trustees of Michigan State University covering tunable luminescent organic salts for enhanced medical imaging and photodynamic therapy applications. The invention relates to novel compositions and methods for diagnostic imaging and therapeutic treatment using organic salt compounds. The patent designates all EU member states and select European countries as protected territories.
What changed
EPO granted patent EP3664892A2 to Board of Trustees of Michigan State University for tunable luminescent organic salt compositions designed for enhanced medical imaging and photodynamic therapy. The patent application, filed by inventors Lunt, Lunt, Broadwater, Young, and Bates, claims compositions and methods for diagnostic imaging and therapeutic applications. The designated states include all EU member states plus other European Patent Convention contracting states.
For pharmaceutical and medical device companies developing imaging agents or photodynamic therapy treatments, this patent establishes intellectual property rights that may restrict freedom to operate in this technological space. Companies should conduct freedom-to-operate analyses before commercializing products in this domain within designated territories.
What to do next
- Monitor patent portfolio for freedom-to-operate implications if developing imaging or photodynamic therapy products
- Review licensing opportunities for luminescent organic salt technology
Archived snapshot
Apr 10, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
TUNABLE LUMINESCENT ORGANIC SALTS FOR ENHANCED IMAGING AND PHOTODYNAMIC THERAPY
Publication EP3664892A2 Kind: A2 Apr 01, 2026
Applicants
Board of Trustees of Michigan State University
Inventors
LUNT, Richard R., LUNT, Sophia Y., BROADWATER, Deanna, YOUNG, Margaret, BATES, Matthew
IPC Classifications
A61K 41/00 20200101AFI20210325BHEP A61K 49/00 20060101ALI20210325BHEP A61P 35/00 20060101ALI20210325BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.